Sage Journals: Discover world-class research

Abstract

Background

Lupus nephritis is one of the most serious complications of systemic lupus erythematosus. This study evaluates the prevalence and correlation between neutrophil gelatinase-associated lipocalin and other biomarkers associated with renal involvement in systemic lupus erythematosus.

Methods

Paired serum and urine specimens from 50 suspected systemic lupus erythematosus patients, characterized by antinuclear antibodies detected by indirect immunofluorescence assay and varying positive concentrations of anti-double stranded DNA antibodies by Crithidia luciliae immunofluorescence assay, were investigated. Of these 50 patients, 18 were identified with renal involvement based upon laboratory serology. Patients and healthy control serum samples (n = 50) were also evaluated for high avidity double stranded DNA IgG antibodies, anti-C1q IgG antibodies, and serum creatinine. The prevalence and relationship between biomarkers were evaluated using statistical methods.

Results

Serum and urine neutrophil gelatinase-associated lipocalin concentrations were significantly elevated in patients compared to controls, with a prevalence of 24% and 36%, respectively. These concentrations were also more markedly increased in systemic lupus erythematosus patients with renal involvement than those without. Spearman’s correlations between neutrophil gelatinase-associated lipocalin and other biomarkers tested ranged from 0.06 to 0.66 in all patients. Combined concordance as determined by Cronbach alpha coefficient between biomarkers was reduced from 0.71 to 0.58 (serum) and 0.62 (urine) when neutrophil gelatinase-associated lipocalin was removed.

Conclusions

Neutrophil gelatinase-associated lipocalin concentrations are elevated and demonstrate variable associated with other laboratory markers for renal involvement in systemic lupus erythematosus. Prospective longitudinal studies are needed to determine the optimal biomarker combinations for use in routine management of systemic lupus erythematosus patients at-risk for lupus nephritis.

Keywords

Neutrophil gelatinase-associated lipocalin systemic lupus erythematosus lupus nephritis biomarkers

Get full access to this article

View all access options for this article.

References

Illei

Tackey

Lapteva

. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048–2065.

Liu

Kao

Manzi

. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis 2013; 5: 210–233.

Cozzani

Drosera

Gasparini

. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014; 2014: 321359–321359.

Jeltsch-David

Muller

. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol 2014; 10: 579–596.

Leffler

Bengtsson

Blom

. The complement system in systemic lupus erythematosus: an update. Ann Rheumat Dis 2014; 73: 1601–1606.

Parodi

Bennett

Brunner

. Biomarkers and updates on pediatrics lupus nephritis. Autoimmune Dis 2013; 39: 833–853.

Petri

. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005; 52: 4003–4010.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

Petri

Orbai

Alarcon

. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

10.

Hahn

McMahon

Wilkinson

. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64: 797–808.

11.

Fiehn

. Early diagnosis and treatment in lupus nephritis: how we can influence the risk for terminal renal failure. J Rheumatol 2006; 33: 1464–1466.

12.

Bolignano

Donato

Coppolino

. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52: 595–605.

13.

Haase

Haase-Fielitz

Bellomo

. Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol 2011; 18: 11–18.

14.

Hinze

Suzuki

Klein-Gitelman

. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009; 60: 2772–2781.

15.

Rubinstein

Pitashny

Levine

. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology 2010; 49: 960–971.

16.

Bock

Heijnen

Trendelenburg

. Anti-C1q antibodies as a follow-up marker in SLE patients. PloS One 2015; 10: e0123572–e0123572.

17.

Tavakol

MDR

. Making sense of Cronbach's alpha. Int J Med Educ 2011; 2: 53–55.

18.

Alharazy

Kong

Mohd

. The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis. Clin Chim Acta 2013; 425: 163–168.

19.

Brunner

Bennett

Mina

. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum 2012; 64: 2687–2697.

20.

Pitashny

Schwartz

Qing

. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007; 56: 1894–1903.

21.

Brunner HI, Mueller M, Rutherford C, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2577–2584.

Comparative analysis of neutrophil gelatinase-associated lipocalin and other laboratory markers for lupus nephritis: a cross-sectional investigation